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First-line therapy of peripheral T-cell lymphoma: extension
and long-term follow-up of a study investigating the role of
autologous stem cell transplantation
M Wilhelm1, M Smetak1, P Reimer2, E Geissinger3, T Ruediger4, B Metzner5, N Schmitz6, A Engert7, K Schaefer-Eckart1 and J Birkmann1
Current guidelines recommend consolidation with autologous stem cell transplantation (autoSCT) after induction chemotherapy for
most patients with peripheral T-cell lymphoma (PTCL). This assumption is based on ﬁve prospective phase II studies, three of which
included o50 patients with limited follow-up. Here we present the ﬁnal analysis of the prospective German study. The treatment
regimen consisted of four to six cycles of CHOP chemotherapy followed by mobilizing therapy and stem cell collection. Patients in
complete remission (CR) or partial remission (PR) underwent myeloablative chemo(radio)therapy and autoSCT. From January 2001
to July 2010, 111 patients were enrolled in the study. The main subgroups were PTCL not speciﬁed (n= 42) and angioimmunoblastic
T-cell lymphoma (n= 37). Seventy-ﬁve (68%) of the 111 patients received transplantation. The main reason for not receiving
autoSCT was progressive disease. In an intent-to-treat analysis, the complete response rate after myeloablative therapy was 59%.
The estimated 5-year overall survival, disease-free survival and progression-free survival rates were 44%, 54% and 39%, respectively.
The results of this study conﬁrm that upfront autoSCT can result in long-term remissions in patients with all major subtypes of PTCL
and therefore should be part of ﬁrst-line therapy whenever possible.
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INTRODUCTION
Peripheral T-cell lymphomas (PTCL) comprise a group of rare and
heterogeneous hematologic malignancies, characterized by an
aggressive disease course chronology in order.1 Despite the fact
that T-cell lymphomas have a poor outcome after conventional
chemotherapy, the optimal therapy for these lymphomas remains to
be determined.2,3 One reason for this is that most studies on the
treatment of T-cell lymphomas are difﬁcult to interpret owing to
retrospective analysis, inclusion of subgroups with a better
prognosis (that is, ALK-positive anaplastic large cell lymphoma
(ALCL)), and small patient numbers.4–10 In addition, owing to the
rarity of the disease, randomized prospective studies are currently
not available. Therefore, for deﬁning a treatment standard, we
must preferentially rely on prospective phase II studies. Owing to
the dismal prognosis of patients with PTCL treated with
conventional chemotherapy, to date, four other prospective
studies speciﬁcally dedicated to PTCL investigated the role of
upfront autologous stem cell transplantation (autoSCT).11–15
In July 2006, Corradini et al.13 published the combined results of
two prospective phase II studies investigating the role of
intensiﬁed sequential chemotherapy followed by upfront autoSCT
in patients with PTCL with estimated 12-year overall survival (OS),
disease-free survival (DFS) and event-free survival (EFS) rates of
34%, 55% and 30%, respectively. These results have to be
interpreted with caution, as 19 of the total 62 patients (31%)
had ALK-positive ALCL, a subentity with a much better prognosis
than all other PTCL entities. The analysis of the remaining 43
patients with PTCL yields an OS of 21% and an EFS estimate
of 18%.
In the small study published by Rodriguez et al.15 in 2007, 19 of
26 patients received autoSCT, with 3-year OS and progression-free
survival (PFS) rates of 85% and 59%, retrospectively.
A Spanish group reported a 4-year OS rate of 39% in 41 patients
with PTCL in 2008. In this study only 41% of the 41 patients
eventually received autoSCT.14
These three studies have a relatively small sample size if the
good prognosis patients are excluded from analysis and therefore,
the possibility of substantial bias needs to be considered.
In January 2009, a paper by our group presented data on
patients with PTCL who were treated with upfront myeloablative
radiochemotherapy and autoSCT following four to six cycles of
conventional chemotherapy.11 For this prospective study, 83
patients were enrolled, excluding ALK-positive ALCL as well as
PCTL. At the time of publication, the estimated 3-year OS, PFS and
DFS rates were 48%, 36% and 53%, respectively.
In July 2012, d’Amore et al.12 published the results of a large trial
of the Nordic Lymphoma Group (NLG-T-01). In this study, 160
patients with PTCL, also excluding ALK-positive ALCL, were treated
with conventional chemotherapy followed by consolidation with
high-dose chemotherapy and autoSCT. The 5-year estimates of OS
and PFS were 51% and 44%, respectively.
This study was ﬁrst published in 2009 when 83 patients had
been included. Additional 28 patients were treated thereafter
according to the study protocol. Here we present the analysis of
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the in total 111 patients with a median follow-up of almost 5
years. Our study is still the largest German study and the second
largest worldwide with a long follow-up.
PATIENTS AND METHODS
Patient characteristics
After this study was reported in 2009 we decided to treat all consecutive
patients according to the study protocol.11 Thus, until July 2010, additional
28 patients were treated exactly as stipulated by the study protocol. The
outcome of these patients is reported together with a follow-up report on
the original cohort of the 83 patients reported previously.
Altogether between January 2001 and July 2010, 111 patients with
newly diagnosed PTCL were treated. Inclusion criteria were as follows:
histologically conﬁrmed PTCL, histology reviewed by the Reference Center
for Lymph Node Pathology in Wuerzburg, Germany, age 18–65 years,
ECOG performance status o4, no severe comorbidity, no pregnancy or
lactation, and written informed consent. The study protocol did not allow
to include patients with primary cutaneous lymphomas and ALCL.
The median age was 49 years (range 23–66 years). The vast majority of
the patients presented with advanced disease: 83 patients (75%) had stage
III–IV disease. The age-adjusted international prognostic index was low/
intermediate low in 44 patients (40%) and intermediate high/high in 64
patients (58%). Patient characteristics are listed in Table 1.
Treatment plan
The treatment plan has been described before.11 In brief, patients received
four cycles of CHOP chemotherapy. If no complete remission (CR) was
achieved, two more cycles were allowed. Patients in CR and patients
achieving at least a partial remission (PR) after six cycles proceeded to
mobilization chemotherapy.
For mobilization of hematopoietic stem cells, the DexaBEAM protocol
(dexamethasone, carmustine, etoposide, cytarabine and melphalan) was
used in 71 of the 84 patients. For 13 patients the ESHAP protocol
(etoposide, methylprednisolone, cytarabine, cisplatin) was administered. A
minimum harvest of 5 × 106 CD34+ cells was required for the patient to be
eligible for high-dose therapy.
Myeloablative radiochemotherapy consisted of fractionated TBI 2×2 Gy/d
on days –6 to –4 for a total dose of 12 Gy, followed by high-dose
cyclophosphamide (60 mg/kg body weight) on days –3 and –2 in 54
patients. As published studies suggest that TBI is not mandatory to give
optimal results in T NHL patients, the more recent patients (n= 21)
received high-dose therapy according to the BEAM protocol (carmustine
300 mg/m2 day –7, etoposide 200 mg/m2 day –6 to day –3, cytarabine
2× 200 mg/m2 also day –6 to day –3, melphalan 140 mg/m2 day –2). On
day 0 autologous stem cells were transfused.
Response criteria
All lesions clinically and/or radiologically involved were measured
bidimensionally by the respective investigator. Treatment response was
assessed as CR, PR, stable disease or progressive disease according to the
Cheson criteria.16 Response was evaluated after four cycles of CHOP
therapy, before myeloablative therapy and when clinical ﬁndings suggest
relapse or progression of disease. After the autoSCT, response was
assessed at 3-month intervals during the ﬁrst two years and at 6-month
intervals thereafter.
Statistical methods
All patients entering the study were evaluated on an intention-to-treat basis.
OS was calculated from the date of diagnosis to the date of death from any
cause. PFS was deﬁned as the period from the date of initiation of treatment
to the date of relapse, disease progression or lost to follow-up. DFS for
patients who achieved a CR was calculated from the date of the ﬁrst
documentation of a CR to the date of the ﬁrst relapse. OS, PFS and DFS rates
were estimated using the Kaplan–Meier method. The median follow-up time
was calculated as proposed by Schemper and Smith.17 Data were run
through the Kaplan–Meier analysis using deaths and censoring reversed. To
identify prognostic variables for OS, univariate analysis was performed.
RESULTS
Treatment response
The intention-to-treat population comprised 111 patients with
PTCL eligible for high-dose chemotherapy. Of these 111 patients,
91 (82%) responded to the initial CHOP therapy. Sixty-nine of
them (62%) achieved a CR, 22 patients (20%) a PR. Twenty patients
(18%) failed to achieve a remission and thus were treated off
study. The course of treatment of the 111 patients is summarized
in Figure 1 and Table 2.
Table 1. Clinical characteristics of patients at diagnosis
n %
Overall 111 100
NOS 42 38
AITL 37 33
ALK-negative ALCL 16 14
Intestinal 7 6
Lennert-lymphoma 1 1
NK/T, nasal-type 5 5
Hepatosplenic 3 3
Median age (years) 49
range 23–66
Sex ratio (male/female) 67:44 60:40
Stage (Ann Arbor)
I or II 28 25
III or IV 83 75
B symptoms 64 58
AaIPI score
Low/low intermediate 44 40
High/high-Intermediate 64 58
Unknown 3 3
Elevated LDH 64 58
Abbreviations: AaIPI, age-adjusted International Prognostic Index; AITL,
angioimmunoblastic T-cell lymphoma; ALCL, anaplastic ALK-negative large
cell lymphoma; LDH, lactate dehydrogenase; NOS, not otherwise speciﬁed;
PTCL, peripheral T-cell lymphoma.
Patients entered Protocol
(n = 111)
Primary refractory
(n = 20)
CR/PR after 6 x CHOP
n = 91 (82%)
PD/Tox/Other
(n = 16)
Transplanted
n = 75 (68%)
Relapse
(n = 32)
Continuous remission after Tx
n = 43 (39% of all patients)
           (57% of Tx-patients)
Figure 1. Course of Treatment of the Study Patients (n= 111). CHOP:
cyclophosphamide, doxorubicin, vincristine and prednisone; CR:
complete remission; PR: partial remission; Tx: stem cell transplanta-
tion; PD: progressive disease; Tox: toxicity.
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Of the 91 responders to initial chemotherapy, 84 patients
started stem cell mobilizing therapy. Seven patients were not
mobilized because of early relapse or withdrawal of consent.
Despite successful mobilization of a sufﬁcient number of stem
cells using either method, only 75 of the 84 patients undergoing
mobilization therapy proceeded to high-dose therapy and
autoSCT. The reasons for not undergoing autoSCT were disease
progression after initial response (n= 5), fatal toxicity (n= 2) and
withdrawal of consent (n = 2). Thus, two-thirds (68%) of the
intention-to-treat population completed the entire study protocol.
The majority of patients (n= 54) received myeloablative radio-
chemotherapy with 12 Gy total body irradiation followed by
120 mg/kg cyclophosphamide, the remaining 21 patients received
high-dose chemotherapy according to the BEAM protocol. Before
high-dose therapy and autoSCT, 63 of these 75 patients (84%)
were in CR and 12 patients (16%) in PR; after the autoSCT
procedure two more patients, that is, 65 patients (87%),
achieved a CR.
Follow-up and survival
Of those 75 patients who completed the whole study treatment,
32 relapsed after autoSCT. With respect to the intention-to-treat
population of 111 patients, 39% achieved a continuous remission.
The estimated 5-year OS, DFS and PFS were 44%, 54% and 39%,
respectively.
At a median follow-up time of 59 months (range 1 to
107 months), 58 patients (52%) were still alive, and 43 of them
(39%) were in continuous remission. In addition, 15 of them (14%)
were alive with disease. Figure 2 show the Kaplan–Meyer plots
with respect to OS (A), DFS (B) and PFS (C). The estimated 5-year
OS rate was 57% for patients who underwent autoSCT compared
with 23% for patients who did not undergo SCT (Figure 3;
P= 0.0003).
Toxicity
Treatment-related morbidity according to the WHO criteria in this
study was comparable with other high-dose studies and did not
signiﬁcantly differ from the earlier reported initial evaluation.
Overall four patients died from treatment-related infectious
complications, resulting in a TRM rate of 3.6%.
Prognostic parameters
In contrast to the results of the International T-cell Lymphoma
Project, univariate analysis regarding the impact of histologic
subtype on OS did not reveal a signiﬁcant correlation as was the
case regarding age, stage, B symptoms and elevated lactate
dehydrogenase. This might be caused by the fact that the
proportion of patients with limited disease and without the
mentioned risk factors was relatively small. In contrast, univariate
but not multivariate analyses revealed that there was a signiﬁcant
correlation between age-adjusted international prognostic index
low/low intermediate vs high/high-intermediate and longer OS
(Figure 4; Po0,02).
DISCUSSION
PTCL represent an aggressive disease with a mostly dismal
prognosis after conventional chemotherapy.1,5,7 Also owing to
their low incidence and their considerable heterogeneity, a
standard therapy has not yet been deﬁned.18,19 With regard to
intensive chemotherapy followed by upfront autoSCT, ﬁve phase II
studies have been reported. (Tables 2 and (1)). Although the
studies published by Rodriguez et al. (n = 14), Mercadal et al.
(n= 41) and Corradini et al. (n = 43) are hampered by relatively
small sample size, our own study ﬁrst published in 2009 had a
relatively short follow-up of 33 months.11,13–15 The trial recently
reported by d’Amore et al.12 comprised a relatively large number
of patients (n = 160), whereas the prospective phase II trial
published by Corradini et al. had the longest follow-up of 76
months.13 Taken together, we believe that all studies added
substantial evidence that intensive chemotherapy followed by
autoSCT is a valid strategy of ﬁrst-line therapy in patients with
PTCL. However, we still felt it difﬁcult to deﬁne upfront autoSCT as
standard therapy in PTCL and therefore decided to extend the
observation time and treat more patients according to the
protocol of our previous study. Here we present the ﬁnal analysis
of 111 patients treated, with a median follow-up of 59 months.
Several aspects of our study are important when comparing the
results with the other trials investigating the role auf autoSCT for
evaluation of treatment standards. All ﬁve PTCL trials are
prospective phase II trials (Table 2) avoiding a bias of analyzing
only chemosensitive patients and patients with potentially more
risk factors (Tables 1 and 2). The vast majority of the patients in
each trial presented with advanced stage disease (from 75 to
96%). Further risk factors, such as B symptoms, elevated serum
lactate dehydrogenase levels or an age-adjusted international
prognostic index of high-intermediate or high, were predominant
in all of the study populations discussed here.6
Before inclusion in our study, reference pathology was
mandatory as it is known that the accurate diagnosis of PTCL
can be challenging with a relatively low likelihood of a concordant
ﬁnal diagnosis at a referring institution.20 Central revision also was
an inclusion criterion in the studies by d’Amore, Mercadal and
Rodriguez.
Table 2. Prospective studies on high-dose therapy and autotransplantation in PTCL as ﬁrst-line therapy
Author n Age Regimen Response before Tx Tx-rate OS Follow-up
Present study 111 49 Cy/TBI or BEAM 62% CR 20% PR
18% PD
68% 44% (5-year) 59
Mercadal14 41 47 BEAM/BEAC 49% CR 10% PR
39% PD
41% 39% (4-year) 38
D´Amore12 160 57 BEAM/BEAC 51% CR 30% PR
16% PD
72% 51% (5-year) 61
Corradini13 a 62 43 Mito/Mel or BEAM 56% CR 16% PR
24% PD
74% 34/21%b (12-year) 76
Rodriguez15 26/14c 44 BEAM 65% CR
12% PR
19% PD
73% 73% (3-year) 35
Abbreviations: CR, complete remission; PD, progressive disease; PR, partial remission; OS, overall survival. aCombined analysis of two separate studies, which
included ALK-positive ALCL. bOS for all patients and non-ALK-positive histology, respectively. cOnly 14/26 patients in this study received autoSCT as upfront
therapy. Analysis includes all patients.
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The International T-cell Lymphoma Project has shown differ-
ences in survival according to histology, with 5-year OS ranges
from 90% for PCTL to 7% for hepatosplenic PTCL.1,4 Therefore,
entities with the best prognosis after conventional chemotherapy
(ALK-positive ALCL and PCTL) usually have not been included in
trials investigating the role of autoSCT as part of ﬁrst-line therapy
except that published by Corradini et al. (in which an additional
analysis excluding ALK-positive ALCL was made). However, with
exception of ALK-positive ALCL in the Corradini trial and ALK-
negative ALCL in the d’Amore trial, subgroup analysis in the other
studies including our own (data not shown) did not reveal
signiﬁcant outcome differences according to the most frequent
subentities. This discrepancy might be explained by the low
number of patients in the relevant subgroups compared with the
International T-cell Lymphoma Project or the ‘equalizing’ effect of
autoSCT.
Conventional chemotherapy consisted of four to six cycles of
the CHOP regimen in all patients in our trial, whereas d’Amore
et al. used the CHOEP-14 regimen in patients age o60 years.12
Corradini et al., Mercadal et al. and Rodriguez et al. used different
induction chemotherapies.13–15 The debate about the best
induction therapy will continue, as neither the more aggressive
drug combinations nor the CHOP protocol, with or without
etoposide, were able to prevent early progression in 16–41% of
the PTCL patients. The retrospective analysis published by Schmitz
et al. on 343 patients treated within trials of the German High-
Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) showed
an improvement of the 3-year event-free survival when etoposide
had been added to the CHOP protocol, but preferentially in the
ALK-positive ALCL group and in patients younger than 60 years
and with normal lactate dehydrogenase levels, that is, in a more
favorable subgroup.21 Similar results for younger patients have
been reported by Ellin et al.3 Likewise, the role of monoclonal
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Figure 2. Kaplan–Meier curves for (a) overall survival, (b) disease-free
survival and (c) progression-free survival.
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Figure 3. Kaplan–Meier curves for overall survival in patients who
did and did not receive transplantation.
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Figure 4. Kaplan–Meier curves for overall survival according to aaIPI
of the patients.
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antibodies like alemtuzumab remains unclear, as any additional
effect on response is hampered by considerable toxicity, especially
life-threatening opportunistic infections.22 Taken together,
although CHOP may not be the ideal protocol for inducing
remission in PTCL, a truly better regimen has not yet been deﬁned.
There is also a lack of standards regarding the optimal
mobilization therapy and/or high-dose protocol before transplan-
tation. Although all reported mobilization therapies proved
effective in yielding a sufﬁcient stem cell harvest, their value for
increasing CR rates is questionable. The same holds true for the
different high-dose chemotherapy and/or radiochemotherapy
protocols, which only moderately contributed to the augmenta-
tion of CR rates, but obviously are of utmost importance for
achieving long-term remissions (Table 2).
This update of the trial published in 2009, reporting more
patients with a longer follow-up, conﬁrms the early study results.
The survival curves did not much deteriorate over time and the
survival plateaus indicate that long-term survival can be achieved
after high-dose therapy/ autoSCT in a substantial fraction of
patients able to proceed to it. Only few deaths occurred beyond
50 months post transplant (Figure 2a). An intention-to-treat
analysis of our study at a median follow-up time of 59 months
reveals that 43 of the 111 patients (39%) achieved a continuous
remission and 58 patients (52%) are still alive, with or without
disease. Despite the fact that different ﬁrst-line chemotherapies
applied slightly differ, the strategy of using a dose-dense
conventional chemotherapy followed by upfront high-dose
chemotherapy with autologous stem cell rescue is very similar in
all prospective trials. In the intention-to-treat patient population, a
long-term OS of 440% and a PFS of 430% can be achieved
(Table 2). A major problem remains that mainly due to failure of
induction therapy and early relapse, only about two-thirds of the
intention-to-treat population will be able to proceed to transplan-
tation. In each trial, patients who completed the whole program
showed signiﬁcantly better OS compared with those who failed
early (Figure 3).
However, it is difﬁcult to identify at diagnosis those patients
who will have the greatest beneﬁt from upfront autoSCT. In an
univariate analysis, IPI deﬁnes risk groups in Corradini, d`Amore,
and Mercadal`s trials, as well as in our patient group. Nevertheless,
different risk groups according to IPI should not alter the
therapeutic strategy, as even IPI low patients have a disappointing
treatment outcome.
Is allogeneic stem cell transplantation (alloSCT) able to improve
results?23–27 Corradini et al.28 conducted a prospective trial using
reduced-intensity conditioning. Owing to the high response rate
and low transplantation-related mortality of this trial, alloSCT was
considered a promising approach in PTCL for younger patients. In
the meantime, a prospective, randomized, European multicenter
trial has been performed (‘AATT trial’) to determine the role of
upfront alloSCT in PTCL. Unfortunately, this study was stopped
prematurely after an interim analysis had shown that the primary
end point, that is, improvement of EFS by alloSCT, could not be
met with the patient numbers planned to be enrolled.29 Thus, at
present, there is no evidence that alloSCT is superior to CHO(E)P
chemotherapy plus upfront autoSCT in ﬁrst-line therapy of most
PTCL. However, for extremely aggressive subtypes, such as
hepatosplenic lymphoma or adult T-cell leukemia/lymphoma
(ATLL), upfront alloSCT might be an option, as graft-versus-
leukemia activity can result in long-term survival in a signiﬁcant
proportion of patients.30–32
The major challenge for the future is to increase response rates
and bring more patients to transplantation. Many new drugs are
being investigated. Brentuximab vedotin and crizotinib appear to
be promising agents in subentities of PTCL.33,34 Romidepsin,
belinostat and pralatrexate yield remarkable responses in relapsed
patients.35–39 Once the phase III trials with these drugs are
ﬁnished, we will know whether these or other new drugs will
improve response rates, allowing more patients to achieve the
possibility of undergoing autoSCT.40
In conclusion, based on available data, upfront autoSCT should
be recommended as a rational choice for patients with the nodal
subtypes PTCL-NOS, AITL, ALK-negative ALCL, as well as high-risk
ALK-positive ALCL eligible for high-dose chemotherapy.5 However,
PFS remains disappointing ranging from 30 to 50%. Nevertheless,
this treatment strategy likely improves the outcome for PTCL
patients compared with conventional chemotherapy.
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